Transdermal HA-Lipid Nanoparticle Delivery of PTEN mRNA in Melanoma

Study Background and Research Question

Melanoma, the most aggressive form of skin cancer, presents persistent treatment challenges due to its high metastatic potential, frequent late-stage diagnosis, and limited efficacy of surgical and pharmacological interventions. While immune checkpoint inhibitors (ICIs) such as anti-PD-1 and anti-CTLA-4 have advanced melanoma management, resistance remains common, often linked to immune evasion mechanisms within the tumor microenvironment (paper). One critical factor is the loss or mutation of phosphatase and tensin homolog (PTEN), a tumor suppressor gene that regulates cell survival pathways and immune infiltration by antagonizing the PI3K/Akt signaling axis.

The central research question addressed in this study is: Can the restoration of PTEN expression in melanoma, using a localized and non-viral mRNA delivery strategy, sensitize tumors to immune intervention and suppress malignant progression?

Key Innovation from the Reference Study

The study's primary innovation lies in developing a hyaluronate-conjugated lipid nanoparticle (HA-LNP) system for the efficient, non-invasive, transdermal delivery of PTEN mRNA (paper). This approach leverages several advances:

• HA-LNP Architecture: By conjugating hyaluronate (HA) to dimyristoyl glycerol (DMG), the researchers created an amphiphilic lipid that integrates into the nanoparticle core during self-assembly, displaying HA moieties on the surface for CD44-mediated targeting and enhanced skin penetration.
• PEG Replacement: The HA-DMG conjugate replaces conventional poly(ethylene glycol) (PEG)-lipids, which are associated with immunogenicity and anaphylaxis risk, thereby improving biocompatibility and reducing adverse reactions.
• Localized, Transdermal mRNA Delivery: The HA-LNPs are optimized for topical administration, enabling deep skin and tumor penetration and selective delivery to CD44-expressing tumor and immune cells.

Methods and Experimental Design Insights

The study utilized a multidisciplinary approach combining materials science, molecular biology, and in vivo pharmacology. Key methodological features include:

• HA-DMG Synthesis and LNP Formulation: HA was covalently linked to DMG, generating an amphiphilic molecule that self-assembles into stable nanoparticles with encapsulated PTEN mRNA during ethanol injection and subsequent purification.
• Particle Characterization: Dynamic light scattering and electron microscopy confirmed uniform particle size and surface presentation of HA.
• In Vitro Functional Testing: Melanoma cell lines (CD44-positive) were treated with PTEN mRNA-loaded HA-LNPs, and PTEN protein restoration, immunogenic cell death (ICD), and cell viability were assessed.
• In Vivo Efficacy: Topical application of PTEN mRNA@HA-LNPs was tested in a melanoma mouse model. Tumor penetration, PTEN expression, immune cell infiltration, tumor growth, and toxicity were systematically evaluated (paper).

Protocol Parameters

• mRNA dose (in vivo topical) | 1–10 μg/site/application | Melanoma mouse model | Balances local expression and safety; higher doses tested for efficacy | paper
• HA-LNP particle size | ~100 nm | Nanoparticle delivery | Sizes <200 nm optimize skin penetration and cellular uptake | paper
• Topical application frequency | Daily for 1–2 weeks | Tumor inhibition studies | Sustained dosing supports tumor suppression | paper
• Storage temperature (for mRNA) | -40°C or below | All mRNA workflows | Minimizes degradation and RNase contamination | product_spec
• Transfection reagent mixing | Premix before adding to serum | In vitro transfection | Prevents mRNA degradation and enhances delivery | workflow_recommendation

Core Findings and Why They Matter

Restoration of PTEN expression in melanoma cells via HA-LNP–delivered mRNA led to several meaningful outcomes:

• Efficient PTEN Expression: Encapsulated mRNA resulted in robust PTEN protein restoration in target cells, reversing PTEN-loss phenotypes (paper).
• Immunogenic Cell Death and Tumor Suppression: Treated melanoma cells displayed increased ICD markers and reduced viability in vitro, while in vivo application significantly inhibited tumor growth and improved immune cell infiltration.
• Minimal Systemic Toxicity: Topical delivery and HA-targeted uptake minimized off-target effects and systemic exposure, enhancing the therapeutic index.
• Overcoming ICI Resistance: By restoring PTEN, the approach re-sensitized tumors to immune clearance mechanisms, counteracting a key resistance pathway in melanoma.

These outcomes support the clinical potential of localized, mRNA-based tumor suppressor gene restoration as a complement or alternative to existing immunotherapies.

Comparison with Existing Internal Articles

Several internal resources reinforce and extend the implications of this study:

• The article "PTEN mRNA Delivery: Mechanisms, Innovations, and Translational Impact" discusses the mechanistic rationale for restoring tumor suppressor gene function in cancer research, highlighting the role of mRNA constructs and advanced delivery systems. It aligns with the reference study’s emphasis on transient, non-integrating mRNA and provides detailed protocol insights for researchers exploring gene therapy research strategies.
• "EZ Cap™ Human PTEN mRNA: Advanced Workflows in Cancer Research" provides practical workflow adaptations and troubleshooting for mRNA transfection and expression, directly referencing innovations like those in the HA-LNP platform. This complements the reference paper’s translational focus by offering stepwise guidance for laboratory implementation.
• Additionally, "EZ Cap™ Human PTEN mRNA: Enhanced Protocols for Tumor Suppressor Restoration" translates findings from HA-LNP and Cap 1 mRNA studies into actionable recommendations for tumor suppressor gene research. It further validates the importance of mRNA stability enhancements (Cap 1 structure, poly(A) tail) for reproducible in vitro and in vivo results.

Limitations and Transferability

Despite promising results, several limitations warrant consideration:

• The study was conducted in a preclinical (mouse) melanoma model; clinical translation will require extensive safety and efficacy validation in humans (paper).
• While HA-LNPs demonstrated selective targeting and low toxicity, their performance across diverse tumor types and patient-specific immune landscapes remains to be determined.
• Transdermal delivery is inherently suited to accessible tumors (e.g., cutaneous melanoma), and its application to internal malignancies may be limited by tissue penetration barriers.
• The stability, translational efficiency, and immune profile of the mRNA construct are influenced by sequence, cap structure, and poly(A) tail—parameters that require meticulous optimization for each application (internal_article).

Research Support Resources

Researchers seeking to replicate or extend these workflows can utilize high-quality reagents such as EZ Cap™ Human PTEN mRNA (SKU R1025). This product features a Cap 1 structure and poly(A) tail to enhance translation efficiency and reduce innate immune activation, supporting robust tumor suppressor gene mRNA studies and mRNA transfection protocols. Protocols should follow best practices for storage, handling, and mixing with transfection reagents, as detailed in APExBIO’s product documentation and as recommended in recent workflow guides.